When do people start losing weight on Wegovy — and what affects the timeline?

The first four weeks: adjustment, not acceleration

Picture this: your first Wegovy pen arrives, tracked by DPD, in a plain box with nothing on the outside to tell a curious neighbour what's inside. You open it, read the leaflet, and take your first injection. Then you wait. And not much happens to the number on the scales.

That is expected, and it is not a sign the medicine isn't working. The opening dose (0.25 mg once a week) is primarily there to let your digestive system settle. Nausea, mild bloating and changes in appetite are common in this phase, and most people find these settle within a couple of weeks. The dose at this stage is not yet high enough to produce the consistent appetite suppression that drives significant weight loss.

Some people do lose a small amount in these early weeks, often partly due to reduced calorie intake from nausea or a general drop in hunger. A kilogram or two is realistic; more than that is a bonus rather than a benchmark, and our guide on when you should start losing weight on Wegovy walks through what a typical early timeline looks like. The full Wegovy overview covers what to expect from each stage of treatment, if you want a broader picture before you start.

Weeks five to sixteen: when weight loss tends to pick up

The dose titration schedule increases semaglutide every four weeks: 0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, before reaching the 2.4 mg maintenance dose. Each step up tends to deepen the appetite-suppressing effect.

For many people, the shift from 0.5 mg to 1.0 mg is when hunger genuinely quietens. You may find meals feel satisfying sooner, snacking feels less automatic, and food simply occupies less mental space. This is the phase where consistent weekly losses (commonly one to two pounds) become more predictable.

By the end of month four, a reasonable number of people have lost 5% or more of their starting weight. That threshold matters clinically: the NHS guidance for semaglutide notes that if less than 5% of body weight has been lost after six months on the maintenance dose, it is worth reviewing whether the treatment is working for that individual. You can read more about how people actually respond to Wegovy across different starting points.

From month four onwards: building towards the trial results

The landmark STEP 1 trial (published in the New England Journal of Medicine) followed 1,961 adults with obesity for 68 weeks. At 2.4 mg weekly, participants lost an average of around 15% of their body weight. That figure represents a long-run average across a diverse group: some lost considerably less, others more. The trajectory is rarely linear either, many people describe periods of faster loss followed by plateaus, then further progress.

What the trial makes clear is that the meaningful results accumulate over six to twelve months, not in the first fortnight. People who reach the maintenance dose and stay consistent with lifestyle changes tend to see the most sustained progress. The experiences of people on Wegovy reflect that same pattern: patience matters as much as the prescription.

For context on how Wegovy's results compare with other licensed weight-loss medicines, the weight-loss treatment overview sets out the options.

What slows (or speeds) the timeline for different people

Several things shape when and how quickly weight loss starts for a given person. Starting BMI plays a role: those with a higher starting weight often see larger absolute losses early on, even if the percentage change is similar. Adherence to a reduced-calorie diet alongside treatment matters more than many people expect, semaglutide reduces appetite but does not override food choices entirely.

GI side effects can affect progress both ways. Nausea that puts you off food in week one may produce early weight loss that then levels off once your body adapts. Conversely, managing side effects by choosing higher-calorie, easier-to-digest foods can slow the process. The NHS semaglutide page has practical guidance on managing common side effects during titration.

Underlying health conditions, other medicines, and individual metabolic differences all influence response. There is no single right answer to when your weight loss will start, which is one reason the prescriber relationship matters throughout treatment, not just at the beginning. If the timeline concerns you, questions about the semaglutide weight-loss timeline are exactly the kind our prescribers hear regularly and are well placed to address.

If you're weighing up the practical side of treatment (including what private Wegovy costs) the Wegovy cost page gives honest context on pricing in the UK. And when you're ready to talk to a prescriber about whether Wegovy is right for you, you can speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered clinician.